Chicago—Findings from a new study challenge current guidelines for the treatment of stage 2 hypertension.
The study's findings, presented at the American College of Cardiology's annual scientific session here in March, found that high-risk patients with hypertension who received a calcium-channel blocker (CCB) combined with an angiotensin-converting enzyme (ACE) inhibitor experienced 20% less cardiovascular morbidity and mortality than did patients taking an ACE inhibitor plus a thiazidetype diuretic. The difference was so significant that the study was stopped early.
Mitka M. CCB/ACE Inhibitor Dual Therapy for Hypertension Lowers Cardiovascular Risk. JAMA. 2008;299(19):2263–2264. doi:10.1001/jama.299.19.2263